Table 1.
BW, HW, infracted area, and baseline hemodynamics in a representative group of CHF and Sham rats after two weeks of Cont-shRNA or Salusin-β-shRNA application.
| Sham | CHF | |||
|---|---|---|---|---|
| Cont | Salusin-β | Cont | Salusin-β | |
| BW (g) | 424 ± 5.9 | 408 ± 21.1 | 415 ± 7.3 | 418 ± 21.6 |
| HW (g) | 1.3 ± 0.1 | 1.2 ± 0.1 | 1.9 ± 0.0† | 1.8 ± 0.1† |
| HW/BW (g/kg) | 3.0 ± 0.1 | 2.9 ± 0.1 | 4.6 ± 0.1† | 4.3 ± 0.2† |
| Infarct size (% LV area) | 0 | 0 | 43.1 ± 1.0† | 30.4 ± 1.0∗† |
| SAP (mmHg) | 142.5 ± 4.2 | 139.8 ± 3.5 | 112.5 ± 3.2† | 122.4 ± 3.6∗† |
| DAP (mmHg) | 103.5 ± 5.1 | 102.5 ± 6.7 | 95.6 ± 7.2 | 86.7 ± 6.2 |
| PP (mmHg) | 39.0 ± 7.2 | 37.2 ± 6.9 | 17.0 ± 2.9† | 35.7 ± 3.0∗ |
| MAP (mmHg) | 119.5 ± 6.7 | 116.2 ± 6.4 | 102.3 ± 5.2† | 97.5 ± 6.1† |
| HR (beats/min) | 386.9 ± 26.2 | 335.9 ± 20.6 | 358.7 ± 38.2 | 375.9 ± 26.1 |
| LVSP (mmHg) | 137.9 ± 6.1 | 129.7 ± 7.3 | 97.9 ± 3.3† | 109.8 ± 4.6∗† |
| LVEDP (mmHg) | 2.5 ± 1.7 | 1.9 ± 1.4 | 13.5 ± 0.7† | 10.3 ± 0.5∗† |
| LVDP (mmHg) | 135.3 ± 6.7 | 127.7 ± 7.0 | 84.5 ± 5.2† | 99.5 ± 4.5∗† |
| LV +dP/dtmax (mmHg/sec) | 3669.8 ± 396.0 | 3725.9 ± 423.0 | 1981.7 ± 133.3† | 3389.6 ± 333.9∗ |
BW: body weight; HW: heart weight; SAP: systolic arterial pressure; DAP: diastolic arterial pressure; PP: pulse pressure; MAP: mean arterial pressure; HR: heart rate; LV: left ventricle; LVSP: left ventricle peak systolic pressure; LVEDP: left ventricle end-diastolic pressure; LVDP: left ventricle developed pressure; LV +dP/dtmax: maximum of the first derivative of left ventricle pressure. Data are given as mean ± SE. ∗P < 0.05 vs. Cont-shRNA. †P < 0.05 vs. Sham. n = 6 for each group.